胆汁酸的肠-肾-肝循环与系统性ASBT抑制剂的靶向治疗潜力

摘要/Abstract

摘要： 近年来的研究发现,肾脏可通过顶端钠依赖性胆汁酸转运蛋白(ASBT)与肝、肠中的许多转运体协同作用,共同参与胆汁酸的重吸收与分布,从而形成胆汁酸的肠-肾-肝循环。在胆汁淤积性肝病中,高胆汁酸血症可促进肾脏通过ASBT介导的滤过胆汁酸重吸收,进而诱发胆汁性肾病,并导致不良预后。系统性ASBT抑制剂能重新定向排泄胆汁酸至尿液,不仅有助于减轻系统胆汁酸负荷,还可实现对靶器官的保护。对胆汁酸的肠-肾-肝轴的深入理解,以及ASBT抑制剂的开发,为肝病患者肝肾肠三重保护提供了新的策略与思路。

关键词: 胆汁酸, 胆汁酸肠-肾-肝循环, 顶端钠依赖性胆汁酸转运蛋白, 胆汁性肾病

金喆, 周达, 刘韬韬. 胆汁酸的肠-肾-肝循环与系统性ASBT抑制剂的靶向治疗潜力[J]. 肝脏, 2026, 31(2): 155-159.

/ 推荐

参考文献

[1] Boyer J L, Soroka C J. Bile formation and secretion: an update [J]. J Hepatol, 2021, 75(1): 190-201.
[2] Chiang J Y L, Ferrell J M. Bile acid metabolism in liver pathobiology [J]. Gene Expr, 2018, 18(2): 71-87.
[3] Dawson P A, Lan T, Rao A. Bile acid transporters [J]. J Lipid Res, 2009, 50(12): 2340-2357.
[4] Ballatori N, Christian W V, Lee J Y, et al. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia [J]. Hepatology, 2005, 42(6): 1270-1279.
[5] Corbett C L, Bartholomew T C, Billing B H, et al. Urinary excretion of bile acids in cholestasis: evidence for renal tubular secretion in man [J]. Clin Sci (Lond), 1981, 61(6): 773-780.
[6] Craddock A L, Love M W, Daniel R W, et al. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter [J]. Am J Physiol, 1998, 274(1): G157-169.
[7] Trauner M, Fuchs C D, Halilbasic E, et al. New therapeutic concepts in bile acid transport and signaling for management of cholestasis [J]. Hepatology, 2017, 65(4): 1393-1404.
[8] Stiehl A, Earnest D L, Admirant W H. Sulfation and renal excretion of bile salts in patients with cirrhosis of the liver [J]. Gastroenterology, 1975, 68(3): 534-544.
[9] Ghallab A, González D, Strängberg E, et al. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis [J]. J Hepatol, 2024, 80(2): 268-281.
[10] Fickert P, Krones E, Pollheimer M J, et al. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice [J]. Hepatology, 2013, 58(6): 2056-2069.
[11] Zhang T, Widdop R E, Ricardo S D. Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers [J]. Am J Physiol Renal Physiol, 2024, 327(5): F788-F805.
[12] Ghallab A, Mandorfer M, Stirnimann G, et al. Enteronephrohepatic circulation of bile acids and therapeutic potential of systemic bile acid transporter inhibitors [J]. J Hepatol, 2025, 83(5): 1204-1217.
[13] Nadim M K, Kellum J A, Forni L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting [J]. J Hepatol, 2024, 81(1): 163-183.
[14] Fickert P, Rosenkranz A R. Cholemic nephropathy reloaded [J]. Semin Liver Dis, 2020, 40(1): 91-100.
[15] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [J]. J Hepatol, 2018, 69(2): 406-460.
[16] Simbrunner B, Trauner M, Reiberger T, et al. Recent advances in the understanding and management of hepatorenal syndrome [J]. Fac Rev, 2021, 10: 48.
[17] Karpen S J, Kelly D, Mack C, et al. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders [J]. Hepatol Int, 2020, 14(5): 677-689.
[18] Caballero-Camino F J, Rodrigues P M, Wångsell F, et al. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans [J]. Hepatology, 2023, 78(3): 709-726.
[19] Hirschfield G, Vandriel S M, Mogul D B, et al. Maralixibat reduces serum bile acids and improves cholestatic pruritus in adolescents with Alagille syndrome [J]. Liver Int, 2025, 45(2): e16201.
[20] Thompson R J, Arnell H, Artan R, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial [J]. Lancet Gastroenterol Hepatol, 2022, 7(9): 830-842.
[21] Trauner M, Karpen S J, Dawson P A. Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease [J]. Hepatology, 2025, 82(4): 855-876.
[22] Desai M S, Mathur B, Eblimit Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart [J]. Hepatology, 2017, 65(1): 189-201.
[23] Abrigo J, Olguín H, Gutierrez D, et al. Bile acids induce alterations in mitochondrial function in skeletal muscle fibers [J]. Antioxidants (Basel), 2022, 11(9)1706.
[24] Perino A, Velázquez-Villegas L A, Bresciani N, et al. Central anorexigenic actions of bile acids are mediated by TGR5 [J]. Nat Metab, 2021, 3(5): 595-603.
[25] Kim D H, Park J S, Choi H I, et al. The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases [J]. Exp Mol Med, 2023, 55(2): 304-312.
[26] Matye D J, Wang H, Luo W, et al. Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis [J]. Cell Mol Gastroenterol Hepatol, 2021, 12(3): 1001-1019.
[27] Slijepcevic D, Roscam Abbing R L P, Fuchs C D, et al. Na(+) -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice [J]. Hepatology, 2018, 68(3): 1057-1069.
[28] Mayo M J, Pockros P J, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis [J]. Hepatol Commun, 2019, 3(3): 365-381.